OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
| Revenue (TTM) | $587.90M |
| Gross Profit (TTM) | $114.48M |
| EBITDA | $-78.17M |
| Operating Margin | -15.30% |
| Return on Equity | -5.88% |
| Return on Assets | -5.52% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $1.67 |
| Price-to-Book | 1.16 |
| Price-to-Sales (TTM) | 2.19 |
| EV/Revenue | 2.178 |
| EV/EBITDA | 49.63 |
| Quarterly Earnings Growth (YoY) | -12.60% |
| Quarterly Revenue Growth (YoY) | 4.30% |
| Shares Outstanding | $742.51M |
| Float | $323.73M |
| % Insiders | 50.52% |
| % Institutions | 27.59% |
Volatility is currently contracting
OPKO Health NASDAQ: OPK reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp.
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. Third Quarter 2026 and Recent Business Highlights OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.
KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly.
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OPK and any ticker you trade — then tracks every position and per-strategy win rate.
